跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 143 条关于
“_PIK3CA_”
全部
143
临床试验
101
药物
5
机构
0
资讯
37
2年前
Inavolisib Shows Promise in PIK3CA-Mutated Advanced Solid Tumors
2年前
Inavolisib Receives FDA Priority Review for PIK3CA-Mutated Breast Cancer
去年
Roche's Itovebi Plus Palbociclib and Fulvestrant Significantly Improves Progression-Free Survival in PIK3CA-Mutated Breast Cancer
去年
Alpelisib Plus Fulvestrant Shows Promise in Advanced Breast Cancer With PIK3CA Mutation
去年
Itovebi-Based Regimen Demonstrates Significant Benefit in PIK3CA-Mutated Breast Cancer
去年
NGS and Targeted Therapies Improve Survival in HR+/HER2- Breast Cancer
去年
Inavolisib Triplet Therapy Improves Outcomes in PIK3CA-Mutant HR+ Breast Cancer
去年
Inavolisib Regimen Significantly Improves Survival in PIK3CA-Mutated Breast Cancer
去年
Allosteric PIK3CA Inhibitors Show Promise in Breast Cancer Treatment
去年
Optimizing Treatment Strategies in HR-Positive Breast Cancer: CDK4/6 Inhibitors, ADCs, and Personalized Approaches
第 1 页,共 4 页
上一页
下一页